Supplementary Figure S3 from The Discovery and Characterization of HBS-101, a Novel Inhibitor of Midkine, as a Therapeutic Agent for the Treatment of Triple-Negative Breast Cancer
<p>Supplementary Figure S3: A, Activity of biotin-HBS-101 on cell viability was analyzed by MTT assay (n = 3). B, The sensitivity of both scrambled and MDK-siRNA BT-549 cells to HBS-101 treatment was evaluated by measuring cell viability with the Cell Titer-Glo assay after 72 hours of treatment. C, The Western blot confirms the successful knockdown of MDK. D, Quantification of the fold change in Annexin V-positive MCF-10A cells is presented as a bar graph. E, To evaluate the effect of HBS-101 on MDK-mediated PI3K/AKT signaling, MDA-MB-231 cells were treated with HBS-101 (20 µM, 15 hrs), and the protein expression levels were analyzed by Western blotting.</p>
Authors
- Dong Liang (ORCID: https://orcid.org/0000-0001-6632-8066)
- Hareesh B. Nair
- Megharani Mahajan (ORCID: https://orcid.org/0000-0002-6259-5754)
- Huan Xie (ORCID: https://orcid.org/0000-0002-0591-5619)
- John R. Sanchez (ORCID: https://orcid.org/0000-0002-5362-1025)
- Jessica D. Johnson (ORCID: https://orcid.org/0000-0002-5331-7461)
- Sridharan Jayamohan (ORCID: https://orcid.org/0000-0002-8430-0881)
- Yang Wang (ORCID: https://orcid.org/0000-0002-0429-9412)
- Suryavathi Viswanadhapalli
- Manjeet K. Rao (ORCID: https://orcid.org/0000-0001-7573-2677)
- Gangadhara R. Sareddy (ORCID: https://orcid.org/0000-0001-9977-3932)
- Panneerdoss Subbarayalu (ORCID: https://orcid.org/0000-0002-9028-7193)
- K.V. Dileep (ORCID: https://orcid.org/0000-0002-7456-4226)
- Ratna K. Vadlamudi (ORCID: https://orcid.org/0000-0003-2849-4076)
- Alondra L. Rodriguez Sanchez
Publication Details
- Published
- 2025-09-02
- DOI
- https://doi.org/10.1158/1535-7163.30028858
- Primary Topic
- Glycosylation and Glycoproteins Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00